Benzinga
Benzinga
Benzinga
lunedì, settembre 21

Tandem Diabetes Care Inc

TNDMNASDAQ
Trade with Public
Trade with Public
$16.87
In chiusura: Sep 21, 5:00 PM EST
$16.78
-0.09-0.53%
Post-mercato: Sep 18, 6:10 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Tandem Diabetes Care Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tandem Diabetes Care (TNDM).

Price Target Range — 11 Quarters

Analyst Consensus — 22 Analysts

13Buy
9Hold
Consensus RatingBuy# Analysts22Avg. Consensus PT$29Upside to Avg. PT+73.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026William BlairSteven LichtmanInitiateOutperform—
Aug 7, 2026CitigroupJoanne WuenschPT RaiseNeutral$17→$21
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating

William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform rating.
Benzinga Newsdesk

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.
Vandana Singh

PRO
Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target from $17 to $21.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $26

RBC Capital analyst Kendall Au maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and lowers the price target from $30 to $26.
Benzinga Newsdesk

PRO
Mizuho Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

Mizuho analyst Anthony Petrone maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.
Benzinga Newsdesk

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.
Avi Kapoor

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved